

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:  
File Information Unit  
Crystal Plaza Three, Room 1D01  
2021 South Clark Place  
Arlington, VA  
Telephone: (703) 308-2733

RECEIVED

OCT 22 2004

File Information Unit

In re Application of

Application Number

Filed

08/246,034

May 18, 1994

Paper No.

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. \_\_\_\_\_, page, \_\_\_\_\_ line \_\_\_\_\_,

United States Patent Number 6231851, column \_\_\_\_\_, line, \_\_\_\_\_ or

WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

## Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:  
For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

## For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:  
the pending application as originally filed.

*Annette Masiello*

Signature

10/22/04

Date

*Annette Masiello*

Typed or printed name

Registration Number, if applicable

703-415-3060

Telephone Number

FOR PTO USE ONLY

Approved by: \_\_\_\_\_

(Initials)

Unit

RECEIVED

OCT 22 2004

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual's involvement on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS OFFICE. Send to: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.



US006231851B1

(12) **United States Patent**  
Platz et al.

(10) Patent No.: **US 6,231,851 B1**  
(45) Date of Patent: **May 15, 2001**

(54) **METHODS AND COMPOSITIONS FOR THE DRY POWDER FORMULATION OF INTERFERONS**

(75) Inventors: Robert M. Platz, Half Moon Bay, CA (US); Shigenobu Kimura, Ako-gun; Yu-ichiro Satoh, Kita-ku, both of (JP); Linda C. Foster, Mountain View, CA (US)

(73) Assignee: Inhale Therapeutic Systems, San Carlos, CA (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 08/737,724

(22) PCT Filed: May 15, 1995

(86) PCT No.: PCT/US95/06008

§ 371 Date: Jul. 14, 1997

§ 102(e) Date: Jul. 14, 1997

(87) PCT Pub. No.: WO95/31479

PCT Pub. Date: Nov. 23, 1995

**Related U.S. Application Data**

(63) Continuation-in-part of application No. 08/246,034, filed on May 18, 1994.

(51) Int. Cl.<sup>7</sup> A61K 38/21; C07K 1/36

(52) U.S. Cl. 424/85.6; 530/351; 514/2

(58) Field of Search 424/85.1, 85.4, 424/85.6, 43, 46, 489, 491; 530/351, 363; 514/12, 21, 777, 776, 2; 435/70.1; 128/200.14, 200.23

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,503,035 3/1985 Pest'ca et al. 424/85.7

4,613,500 \* 9/1986 Suzuki et al. 424/85.4  
4,812,444 \* 3/1989 Mitsubishi et al. 514/53  
4,847,079 \* 7/1989 Kwan 424/85.7  
4,895,719 1/1990 Radhakrishnan 424/45  
5,049,389 \* 9/1991 Radhakrishnan 424/450  
5,284,656 \* 2/1994 Platz et al. 424/435  
5,354,562 10/1994 Platz 424/489  
5,354,934 10/1994 Pitt 514/8

**FOREIGN PATENT DOCUMENTS**

WO 89/05158 6/1989 (WO).  
WO 91/16882 5/1991 (WO).  
91/16038 \* 10/1991 (WO).  
93/00951 \* 1/1993 (WO).

**OTHER PUBLICATIONS**

Wyde et al. Pulmonary Deposition and Clearance of Aerosolized Interferon. Antimicrobial Agents and Chemotherapy. 25 (6): 729-734, Jun. 1984.\*

Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Co., Chap. 88, Powders, p. 1615; Chap. 89, Oral Dosage Forms, pp. 1646-1647.

\* cited by examiner

Primary Examiner—David Guzo

Assistant Examiner—Jon Shuman

(74) Attorney, Agent, or Firm—Susan T. Evans; Felissa H. Cagan; Stephen L. Hurst

(57) **ABSTRACT**

According to the present invention, methods and compositions are provided for spray-dried, interferon-based dry powder compositions, particularly interferon-beta. The compositions are useful for treating conditions in humans that are responsive to treatment with interferons. In particular, the methods of the present invention rely on spray drying to produce stable, high-potency dry powder formulations of interferons, including but not limited to IFN-beta. Surprisingly, it has been found that IFN can be prepared in high potency, dry powder formulations by spray drying. Such dry powder formulations find particular utility in the pulmonary delivery of IFN.

25 Claims, No Drawings